ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 803.2 USD | +2.55% |
|
+5.13% | +37.78% |
| 06:42am | Eli Lilly Reports Positive Trial Results for Crohn's Disease Treatment | MT |
| 06:27am | China Grants Green Light to Eli Lilly's Diabetes Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.78% | 723B | |
| +31.23% | 598B | |
| -3.51% | 364B | |
| +19.94% | 331B | |
| +5.14% | 288B | |
| +15.81% | 244B | |
| -4.46% | 208B | |
| +9.94% | 210B | |
| +9.32% | 169B | |
| -0.80% | 162B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- BMO Capital Adjusts Eli Lilly Price Target to $1,001 From $900
